Using wearable devices to prevent hospitalizations during cancer treatment
Wearable Activity Tracking to Curb Hospitalizations (WATCH)
University of California, San Francisco · NCT06587100
This study is testing whether using wearable devices can help predict and prevent hospital visits for patients getting radiation therapy for cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 260 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT06587100 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect patient-generated health data through wearable devices to predict the risk of emergency department visits or hospitalizations for patients undergoing radiation therapy for various malignancies. Participants will be assigned to one of two groups, receiving either a Fitbit device or using their own Apple HealthKit-based device while receiving standard care. The study will validate existing predictive models based on step counts and electronic health records to enhance the understanding of patient activity levels and their correlation with acute care needs. The ultimate goal is to develop a multi-modal predictive model that can improve patient outcomes during treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of invasive malignancy who can ambulate independently and are scheduled for radiation therapy.
Not a fit: Patients who are wheelchair-bound or require assistance to ambulate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the number of hospitalizations for cancer patients undergoing radiation therapy by enabling proactive interventions.
How similar studies have performed: Other studies utilizing wearable technology for health monitoring have shown promise, suggesting that this approach may yield beneficial results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>= 18. * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2. * Able to understand study procedures and to comply with them for the entire length of the study. * Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it. * Diagnosis of invasive malignancy. * Able to ambulate independently (without the assistance of a cane or walker). * Planned treatment with fractionated external beam radiotherapy over at least 5 days (no fractional requirement). * Not a previous participant on this protocol for subsequent courses. Exclusion Criteria: * Participants bound to a wheelchair. * Participants unable to ambulate independently (needing assistance of cane or walker).
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (RECRUITING)
Study contacts
- Principal investigator: Julian Hong, MD, MS — University of California, San Francisco
- Study coordinator: Imani Dunn
- Email: Imani.Dunn@ucsf.edu
- Phone: 877-827-3222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm, Activity tracking, Hospitalization prevention, Artificial Intelligence modelling